Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 6-Month, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group, Maintenance Of Effect Study Of Esreboxetine (PNU-165442g) Administered Once Daily (QD) In Patients With Fibromyalgia

Next Previous
Trial Profile

A 6-Month, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group, Maintenance Of Effect Study Of Esreboxetine (PNU-165442g) Administered Once Daily (QD) In Patients With Fibromyalgia

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esreboxetine (Primary)
  • Indications Fibromyalgia
  • Focus Therapeutic Use
  • Sponsors Pfizer

Most Recent Events

  • 18 Aug 2012 Actual initiation date (14 Jan 2009) added as reported by European Clinical Trials Database.
  • 17 Mar 2009 Status changed from not yet recruiting to withdrawn prior to recruitment, as reported by clinicaltrials.gov.
  • 25 Feb 2009 Pfizer has decided to discontinue development of this drug, as reported in a media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top